NeuroPace Inc
NPCE- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001528287
No open-market purchases or sales by NeuroPace Inc insiders were filed in the last 90 days; 112 institutions reported holding it in 13F filings for Q2 2026, worth $422.4M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding NeuroPace Inc changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 28 | 1 | 24 | −3 |
| Shares | 18.2M | 43.0K | 17.4M | −760.9K (−4.2%) |
| Value | $68.1M | $161.0K | $25.9M | −$42.1M (−61.9%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (1)
Institutions that held NeuroPace Inc at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jacobs Levy Equity Management, Inc | 23,692 | $35.3K | 0.00% |
Sold out (4)
Institutions that held NeuroPace Inc at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Bellevue Group AG | 388,368 | $1.46M |
| Point72 Asset Management, L.P. | 145,703 | $546.0K |
| Opaleye Management Inc. | 116,324 | $436.0K |
| Ergoteles LLC | 31,027 | $116.0K |
Not filed for Q4 2022 yet (1)
Institutions that held NeuroPace Inc at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Revelation Capital Management, LLC | 42,972 | $161.0K |